InMed Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . InMed Pharmaceuticals
INM Stock  USD 1.00  0.06  6.38%   
InMed Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing InMed Pharmaceuticals' valuation are provided below:
Gross Profit
1.6 M
Profit Margin
(1.71)
Market Capitalization
2.6 M
Enterprise Value Revenue
0.1247
Revenue
4.8 M
There are over one hundred nineteen available fundamental trends for InMed Pharmaceuticals, which can be analyzed over time and compared to other ratios. Self-guided Investors are advised to confirm InMed Pharmaceuticals' regular fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. As of the 11th of February 2026, Market Cap is likely to drop to about 16 M. In addition to that, Enterprise Value is likely to drop to about 13.8 M

InMed Pharmaceuticals Total Revenue

5.97 Million

Check InMed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InMed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 289 K, Interest Expense of 352.6 K or Selling General Administrative of 7.9 M, as well as many indicators such as Price To Sales Ratio of 10.83, Dividend Yield of 0.0 or Days Sales Outstanding of 34.42. InMed financial statements analysis is a perfect complement when working with InMed Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with InMed Stock
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

InMed Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets18.8 M17.9 M9.6 M
Slightly volatile
Total Current Liabilities1.2 M2.1 M1.2 M
Slightly volatile
Property Plant And Equipment Net1.2 M1.1 M565.6 K
Slightly volatile
Accounts Payable641.4 K425.7 K549 K
Slightly volatile
Cash13.4 M12.7 M6.3 M
Slightly volatile
Non Current Assets Total3.3 M3.1 M2 M
Slightly volatile
Other Assets114.6 K120.6 K883.2 K
Pretty Stable
Cash And Short Term Investments13.4 M12.7 M6.8 M
Slightly volatile
Net Receivables439.5 K418.6 K149.1 K
Slightly volatile
Common Stock Shares Outstanding1.2 M1.1 M226.3 K
Slightly volatile
Short Term Investments47.6 K50.1 K6.3 M
Slightly volatile
Liabilities And Stockholders Equity18.8 M17.9 M9.6 M
Slightly volatile
Non Current Liabilities Total271.5 K351.6 K331.5 K
Pretty Stable
Other Current Assets219.8 K419.9 K314.3 K
Slightly volatile
Other Stockholder Equity47.5 M45.2 M19.9 M
Slightly volatile
Total Liabilities1.3 M2.5 M1.4 M
Slightly volatile
Total Current Assets15.5 M14.8 M7.8 M
Slightly volatile
Intangible Assets961.3 K1.9 M1.3 M
Slightly volatile
Short and Long Term Debt Total895.1 K852.5 K473.7 K
Slightly volatile
Short Term Debt525.9 K500.8 K202.5 K
Slightly volatile
Good Will1.4 M2.3 M1.9 M
Slightly volatile
Common Stock56.9 M104.9 M53.7 M
Slightly volatile
Common Stock Total Equity52.6 M69.7 M49.9 M
Slightly volatile
Net Tangible Assets9.1 M9.1 M9.3 M
Pretty Stable
Net Invested Capital8.7 M12.1 M9.1 M
Slightly volatile
Net Working Capital7.3 M9.9 M7.6 M
Slightly volatile
Property Plant Equipment873.5 K831.9 K350.4 K
Slightly volatile
Capital Stock76.3 M104.9 M63.8 M
Slightly volatile
Capital Lease Obligations658.4 K852.5 K528.8 K
Slightly volatile
Property Plant And Equipment Gross1.6 M2.7 M1 M
Slightly volatile

InMed Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization289 K481.3 K351.3 K
Very volatile
Selling General Administrative7.9 M7.5 M4.4 M
Slightly volatile
Other Operating Expenses15.5 M14.8 M8 M
Slightly volatile
Cost Of Revenue3.9 M3.7 M1.1 M
Slightly volatile
Total Operating Expenses11.6 M11.1 M7 M
Slightly volatile
Research Development2.4 M3.3 M2.5 M
Slightly volatile
Selling And Marketing Expenses6.3 B6 B2.3 B
Slightly volatile
Reconciled Depreciation340.9 K614.9 K246.9 K
Slightly volatile
Interest Income272.6 K179.3 K179.6 K
Slightly volatile

InMed Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow7.9 M7.6 M5 M
Slightly volatile
End Period Cash Flow13.4 M12.7 M6.2 M
Slightly volatile
Stock Based Compensation102 K107.4 K837.2 K
Pretty Stable
Change To Netincome542.3 K570.8 K1.7 M
Pretty Stable
Issuance Of Capital Stock8.6 M9.3 M4.4 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.8311.40151.6187
Slightly volatile
Days Sales Outstanding34.4236.236636.8569
Slightly volatile
Average Payables141 K148.5 K471.6 K
Pretty Stable
Stock Based Compensation To Revenue0.02640.02780.4583
Slightly volatile
Inventory Turnover104110126
Slightly volatile
Days Of Inventory On Hand3.173.33241.4 K
Slightly volatile
Payables Turnover1.672.68161.7283
Slightly volatile
Sales General And Administrative To Revenue1.451.534.6194
Slightly volatile
Average Inventory57.7 K60.7 K915.5 K
Pretty Stable
Research And Ddevelopement To Revenue0.490.524.5276
Slightly volatile
Capex To Revenue0.00810.00850.0272
Slightly volatile
Cash Per Share3.353.5288766
Pretty Stable
Days Payables Outstanding1291361.7 K
Slightly volatile
Income Quality0.530.31860.67
Pretty Stable
Intangibles To Total Assets0.320.39560.3778
Slightly volatile
Current Ratio0.320.33285.5932
Very volatile
Receivables Turnover5.0610.07279.8424
Pretty Stable
Capex Per Share4.134.354.5711
Pretty Stable
Average Receivables155.7 K233.9 K135 K
Slightly volatile
Revenue Per Share7385121 K
Slightly volatile
Interest Debt Per Share31.6933.3564102
Very volatile
Debt To Assets0.330.24950.0991
Very volatile
Operating Cycle37.5939.5691.5 K
Slightly volatile
Days Of Payables Outstanding1291361.7 K
Slightly volatile
Ebt Per Ebit0.820.931.012
Slightly volatile
Quick Ratio0.30.31835.4316
Very volatile
Net Income Per E B T0.80.90.9783
Slightly volatile
Cash Ratio0.01810.01914.5933
Very volatile
Days Of Inventory Outstanding3.173.33241.4 K
Slightly volatile
Days Of Sales Outstanding34.4236.236636.8569
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.211.191.0302
Slightly volatile
Fixed Asset Turnover22.5926.63756.7369
Very volatile
Debt Ratio0.330.24950.0991
Very volatile
Price Sales Ratio10.8311.40151.6187
Slightly volatile
Asset Turnover4.023.83330.8164
Pretty Stable
Gross Profit Margin0.450.42640.4432
Pretty Stable

InMed Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap16 M23.9 M20.7 M
Very volatile

InMed Fundamental Market Drivers

InMed Upcoming Events

16th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About InMed Pharmaceuticals Financial Statements

InMed Pharmaceuticals investors utilize fundamental indicators, such as revenue or net income, to predict how InMed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-849.6 K-892.1 K
Total Revenue5.7 M6 M
Cost Of Revenue3.7 M3.9 M
Stock Based Compensation To Revenue 0.03  0.03 
Sales General And Administrative To Revenue 1.53  1.45 
Research And Ddevelopement To Revenue 0.52  0.49 
Capex To Revenue 0.01  0.01 
Revenue Per Share 512.44  738.43 
Ebit Per Revenue(0.59)(0.62)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
How To Invest In InMed
Details
Is InMed Stock a good investment?
Details
What is InMed Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Will Biotechnology sector continue expanding? Could InMed diversify its offerings? Factors like these will boost the valuation of InMed Pharmaceuticals. Market participants price InMed higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every InMed Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share
(6.09)
Revenue Per Share
1.213
Quarterly Revenue Growth
(0.11)
Return On Assets
(0.42)
Return On Equity
(0.82)
Understanding InMed Pharmaceuticals requires distinguishing between market price and book value, where the latter reflects InMed's accounting equity. The concept of intrinsic value - what InMed Pharmaceuticals' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push InMed Pharmaceuticals' price substantially above or below its fundamental value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, InMed Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY